Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Smith & Nephew Plc | SN. | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 1.20 | 0.12% | 976.00 | 11:53:23 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 982.00 | 971.00 | 982.20 | 974.80 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
|---|---|---|---|---|---|---|
| 27/02/2024 | Final | USD | 0.231 | 28/03/2024 | 02/04/2024 | 22/05/2024 |
| 03/08/2023 | Interim | USD | 0.144 | 05/10/2023 | 06/10/2023 | 01/11/2023 |
| 21/02/2023 | Final | USD | 0.231 | 30/03/2023 | 31/03/2023 | 17/05/2023 |
| 28/07/2022 | Interim | USD | 0.144 | 29/09/2022 | 30/09/2022 | 26/10/2022 |
| 22/02/2022 | Final | USD | 0.231 | 31/03/2022 | 01/04/2022 | 11/05/2022 |
| Top Posts |
|---|
Posted at 06/11/2024 12:13 by uhound SN. Price target cut to £10.50 by Berenberg.However, some would say this is now offering very good value. |
Posted at 05/11/2024 00:24 by philanderer On Monday, Canaccord Genuity adjusted its outlook for medical equipment manufacturer Smith & Nephew (NYSE: SNN), reducing the price target from $32.00 to $27.00 while keeping a Hold rating on the stock.(Two ordinary shares of Smith & Nephew (SN) are represented by one American Depositary Share (ADR). |
Posted at 05/11/2024 00:16 by philanderer Jefferies cuts Smith & Nephew target but stays optimisticJefferies has slashed its target price for medical devices maker Smith & Nephew from 1,400p to 1,250p after challenges in China weighed heavily on third-quarter results. Nevertheless, the broker kept a 'buy' rating on the stock, saying that the shares' valuation is undemanding by historical standards. Smith & Nephew reported on Thursday that it was cutting its 2024 and 2025 guidance on the back of struggles in China, where it was impacted by worse-than-expected headwinds across the surgical businesses. "This is a clear step back as investors were slowly starting to reward management for improved visibility and consistency," Jefferies said in a research note on Monday. "While unhelpful, China setbacks seem temporary and SN is slowly reaping the benefits from portfolio shifting toward faster-growth segments and recent R&D efforts, which support higher, sustainable growth." The stock has dropped by around 20% over the past three months, leaving its close to an all-time low price-to-earnings ratio of just 12.5. Jefferies said it sees "ample room for [a] re-rating". Sharecast |
Posted at 31/10/2024 10:02 by essentialinvestor SN has had a succession of CEO's over the last decade, each with a different action plan, areas of focus, yet the result has been similar - early promise followed by disappointment.A bid may be the best hope. The balance sheet, once rock solid, has been geared through acquisitions. |
Posted at 03/10/2024 07:54 by uhound Ex- Divi date today. |
Posted at 01/8/2024 07:43 by foreverbull Q2 Trading Highlights1,2· Q2 revenue of $1,441 million (Q2 2023: $1,379 million), up 5.6% (4.6% on a reported basis including -100bps FX headwind)· Orthopaedics revenue up 5.8% (4.9% reported), with good growth across Hip and Knee Implants outside the US, Other Reconstruction and Trauma & Extremities; further progress in addressing performance in US Hip and Knee Implants· Sports Medicine & ENT up 7.6% (6.3% reported), with strong growth across all segments; continued headwind from China sports medicine VBP· Advanced Wound Management up 3.3% (2.3% reported), returning to growth with all segments contributing H1 Highlights1,2· H1 revenue of $2,827 million (H1 2023: $2,734 million), up 4.3% (3.4% on a reported basis including -90bps FX headwind)· Operating profit of $328 million (H1 2023: $275 million), up 19.5% reported· Trading profit up 12.8% to $471 million (H1 2023: $417 million)· Trading profit margin expansion to 16.7% (H1 2023: 15.3%), around the top of our guided range, reflecting positive operating leverage and 12-Point Plan benefits· Cash generated from operations $368 million (H1 2023: $215 million)· Significant improvement in trading cash flow conversion at 60% (H1 2023: 26%), trading cash flow increased to $284 million (H1 2023: $110 million)· Adjusted earnings per share ('EPSA') up 7.7% to 37.6¢ (H1 2023: 34.9¢). Basic earnings per share ('EPS') was 24.5¢ (H1 2023: 19.7¢)· Interim dividend of 14.4¢, in line with prior year Outlook1,2· 2024 guidance unchanged: underlying revenue growth expected in the range of 5.0% to 6.0% (4.4% to 5.4% reported), and trading profit margin expected to be at least 18.0%· Midterm targets unchanged Strategic Highlights1,2· 12-Point Plan benefits driving improved financial performance:o Orthopaedics turnaround delivering strong results across Trauma & Extremities, Other Reconstruction and Hip and Knee Implants outside of the US. Performance from Hip and Knee Implants in the US expected to improve through the second half of 2024o Productivity improvements supporting trading margin expansion; further savings identifiedo Advanced Wound Management and Sports Medicine & ENT on track for another year of strong growth· Sustained high cadence of new product launches to drive future higher growth Deepak Nath, Chief Executive Officer, said:"Today's results are further evidence of the good progress we are making transforming Smith+Nephew into a higher growth and more profitable business."Across the majority of Orthopaedics, which was our underperforming business unit, we are now consistently achieving growth rates well above historical levels. The methods we employed in achieving these successes give me confidence that we will also turn around US Hip and Knee Implants and we expect to see a step up through the second half of the year."Our investment in innovation continues to deliver. In the first half of 2024, we delivered several major launches and product enhancements. For example, we continued to expand our CORI? Surgical System, which is now a recognised leader in robotics-assisted surgery. We also achieved full commercial launch of our AETOS? Shoulder System, addressing one of the fastest growing segments in Orthopaedics, and US regulatory approval for our new CATALYSTEM? Hip System."Our progress is also showing through in our double-digit trading profit growth and margin expansion, driven by positive operating leverage and efficiency initiatives. I am pleased to see this profit growth translate into cash flow, with our first-half trading cash flow up more than 150% year-on-year."Our guidance for the full year remains unchanged. There is still more work to be done and we expect to see further progress in the second half of the year." |
Posted at 18/7/2024 14:26 by foreverbull Are you meaning to say he could have bought SN shares which would have helped him make (or loose) more money? |
Posted at 04/7/2024 07:46 by foreverbull Smith & Nephew Snats (SN) has released an update.Smith & Nephew PLC has notified a change in major holdings, with Norges Bank crossing the threshold on June 28, 2024, now holding a total of 3.054% voting rights. This significant financial activity, reported on July 3, 2024, reflects a combination of voting rights attached to shares and financial instruments, amounting to over 26 million voting rights within the medical equipment manufacturer. |
Posted at 07/6/2024 06:54 by socionomics The good news for SN investors is that we're heading into Wave 5, so we should break the £20 high in due course. The bad news is that's a 5-6 year move. Might be a little too boring for many, but for me it's an easy SIPP play.DYOR as always. |
Posted at 30/4/2024 04:17 by alotto Smith and nephew has always been way overpriced. Even at the current level still seems overpriced. The dividend payout is below what you get from a saving account and the prospect for growth is just about meh.The share price should be half as much to yield a healthy dividend of 5-6%. I would buy only with the wish of seeing the share price back to historical levels but I can't put any weight behind my wish especially with the debt it carries and the rates. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
